Related Experiment Video

Updated: May 29, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.3K

Clinical trials targeting tau should be halted

Andi Olluri1

  • 1Independent and unaffiliated student, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|February 5, 2025
PubMed

Insights

Clinical trials for experimental Alzheimer's disease drugs targeting tau protein have consistently failed to show patient benefits. The scientific basis for these anti-tau therapies is weak, suggesting a need to halt further drug development.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Tau protein pathology is a key hallmark of AD.
  • Experimental drugs targeting brain tau are under investigation for AD treatment.
Keywords:
Alzheimer’s diseaseAmyloidAntibodyClinical trialDementiaMedicineTau

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.9K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437